Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
Quizartinib significantly improves long-term survival in FLT3-ITD+ AML by achieving deep and sustained reductions in MRD.
Combining HMAs with venetoclax significantly improves remission rates and survival but requires more healthcare resources.
SLC40A1 mRNA levels were significantly higher in AML patients compared with controls and were associated with poorer OS.
Achieving complete hematologic recovery before subsequent treatment cycles is associated with improved survival outcomes.
Combining genomic markers and clinical parameters increased the accuracy of predicting treatment response in pediatric ALL.
Lisaftoclax yielded promising progression free survival in elderly patients and in those with relapsed or refractory disease.
Advertisement
Olutasidenib achieved rapid and durable responses in patients, including those relapsed or refractory to venetoclax.
Revumenib monotherapy achieved high overall response rates and MRD negativity rates.
Patients with BCR::ABL1+AML have better outcomes than those with intermediate- or adverse-risk disease.
ATRA-ATO showed improved efficacy versus ATRA with standard chemotherapy in high-risk APL.
In a phase Ib sub-study, adding revumenib to azacitidine plus venetoclax therapy produced promising response results.
In an ongoing, phase I/II trial, DSP-5336 achieved an objective response rate of 57% and a CR/CRh rate of 24%.
Christophe Willekens, MD, compares standard dosing venetoclax for AML to seven-day dosing plus azacitidine.
A reduced venetoclax exposure of seven days was comparable with continual venetoclax exposure in patients with AML.
The first analysis from a phase 1b study shows combination has efficacy even in patients previously on venetoclax.
The updated findings are from a prospective phase II trial presented at the EHA 2024 Hybrid Congress.
Patients who responded to treatment achieved more than 90% bone marrow blast reduction compared with baseline.
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
The patient, a 63-year-old male, was diagnosed with HIV-1 infection 31 years before undergoing transplantation.
Oral tamibarotene is currently being evaluated in combination with azacitidine and venetoclax in the SELECT-AML-1 trial.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.